肿瘤异常蛋白（TAP）在肝癌诊断及预后评估中的应用价值

摘要

Objective:To investigate the serum tumor abnormal protein(TAP)levels and its relevance in diagnosis and recurrence assessment of patients with Hepatocellular Carcinoma .Methods :50 cases of liver cancer group、benign liverdisease group and healthy people as control group were selected ,serum TAP、AFP of patients and healthy people mentioned above were detected .observed the changes and its relationship to relapse‐free survival (RFS) .Results :Serum levels of TAP of patients in primary liver cancer group were significant higher than those in benign liver disease group and control group(P<0 .05) .Sensitivity of TAP detection combined with AFP in primary liver cancer diagnosis was obvious higher than those in detection groups without TAP(P<0 .05) .Conclusion :Aver‐age TAP concentration of 50 cases of liver cancer patients after 1 months were significantly lower than those before surgery(P<0 .05) .Furthermore ,one month after surgery ,the relapse‐free survival(RFS) of patients whose TAP level achieved PR was significantly longer than that of SD+PD group(P<0 .05) .Conclusion:Serum TAP as a new tumor marker has potential applications in the diagnosis and assessment of recurrence of hepatocellular carcinoma .%目的：探讨肿瘤异常蛋白（TAP）在肝癌患者中的表达水平及对肝癌的诊断价值和复发评估作用。方法：选取原发性肝癌患者、良性肝病患者及健康体检者各50例，分别检测各组TAP、AFP水平，比较分析各组TAP水平差异以及术后 TAP变化情况与肝癌患者无复发生存率（RFS）的相关性。结果：原发性肝癌组患者 TAP水平显著高于良性肝病组与对照组（P＜0．05）， TAP与AFP联合检测对原发性肝癌的诊断敏感性显著高于单独检测组（P＜0．05）。50例肝癌患者的TAP术后1个月水平较术前显著下降，且以术后1个月 TAP水平评估为PR组的患者无复发生存率（RFS）显著高于SD＋PD组（P＜0．05）。结论：肿瘤异常蛋白（TAP）作为新的肿瘤标志物，在肝癌的诊断和复发评估中有着潜在的应用价值。